CD20 x CD3 Bispecific Antibodies in Non-Hodgkin Lymphoma Management

This chapter discusses the concept of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma, highlighting different agents, their efficacy and tolerability, and the potential for cytokine release syndrome. It compares Nautuzumab and Odronextamab, emphasizing their similar outcomes. The chapter also explores the importance of dose step up, treatment duration, and administration methods, and discusses the challenges and implications of using Glufida map and other combination therapies.